"Imugene’s PD1-Vaxx is a B-cell activating immunotherapy designed to treat tumours such as lung cancer by interfering with PD-1/PD-L1 binding and interaction.
It produces an anti- cancer effect similar to Tecentriq®, Keytruda®, Opdivo® and the other immune checkpoint inhibitor monoclonal antibodies that are transforming the treatment of a range of cancers".
Notice it doesn't say 'in combination with'?
If we have a 'as good as Keytruda' or better product (and the preliminary results suggest way better) then look up the combined sales of Keytruda etc.
When the flag drops on IMU, it is going to be worldwide news IMO.
Who cares about EOFY, I'm not selling.
DYOR.
Ann: Imugene PD1-Vaxx patent extended to 2040, page-10
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
-0.001(1.02%) |
Mkt cap ! $360.7M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 5.0¢ | 4.8¢ | $451.5K | 9.226M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 82 | 10208835 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 1180208 | 27 |
View Market Depth
| Last trade - 15.51pm 08/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |